Discover

News & Info

Quote List Quote List

HENLIUS(02696.HK)

Event Tracking

Apr14

Fosun Pharma's Subsidiary Approved to Conduct Clinical Trials for HLX05-N in Metastatic Colorectal Cancer Treatment

08:46

Apr10

Ful ひ宏汉霖 Completes First Dose Administration in Phase 1 Clinical Trial for HLX319

08:55

Apr9

Fosun Pharma's Subsidiary's Hanlikang New Indication Approved

09:07

Apr2

Fanhong Hanlin Announces 2025 Annual Report, Facing Pressure for Innovation Transformation

12:36

Apr1

Fosun Pharma's Subsidiary Obtains Approval for HLX319 Phase I Clinical Trials for Breast Cancer

08:58

Mar31

Fosun Pharma's Subsidiaries Receive Approval for Two Drug Clinical Trials

09:30

Schedules & Filings

Schedules

Filings

Mar20

Earning Release(CST)

FY2025 Q4 Earning Release (HKD) Revenue 2.139 B, Net Income 242.93 M, EPS 0.439

Aug25

Earning Release(CST)

FY2025 Q2 Earning Release (HKD) Revenue 1.543 B, Net Income 213.5 M, EPS 0.3928

Mar24

Earning Release(CST)

FY2024 Q4 Earning Release (HKD) Revenue 1.584 B, Net Income 230.95 M, EPS 0.4249

View More

Stock List

Top Gainers

Top Decliners

Main Board

Symbol

Price

%Chg

Change

View More